Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

2018 Dengvaxia (tetravalent live-attenuated chimeric vaccine; Sanofi Pasteur) Drug Analysis - ResearchAndMarkets.com

Research and Markets
Posted on: 21 Feb 18

The "Drug Analysis: Dengvaxia" drug pipelines has been added to ResearchAndMarkets.com's offering.

Dengvaxia (tetravalent live-attenuated chimeric vaccine; Sanofi Pasteur) is a tetravalent vaccine comprised of four monovalent, chimeric live-attenuated vaccines (LAVs). The vaccine is currently approved in 19 dengue-endemic markets, although to date pilot public sector vaccination campaigns have only been initiated in Brazil and the Philippines.

Although Dengvaxia has the potential to address a major unmet need as the first-to-market dengue fever vaccine, its initial uptake has been disappointingly slow due to protracted pricing and reimbursement negotiations and uncertainty regarding the optimal rollout strategy for the vaccine in emerging markets. Moreover, uptake is expected to be further hampered by safety concerns in seronegative patients, which have led national authorities in Brazil to restrict the vaccine's use, and those in the Philippines to suspend its marketing authorization.

The author believes that Dengvaxia's sales will only rise in 2018 if Sanofi manages to achieve a successful rollout of public sector vaccination programs, as well as if it continues the rollout of the vaccine in the private sector of an increasing number of dengue-endemic markets. Given the delays to the incorporation of Dengvaxia into the public sectors of lower- and middle-income markets, private sector sales will be critical in ensuring that Sanofi achieves a return on investment before the anticipated launch of additional vaccines from 2019.

From this time, Dengvaxia faces the threat of obsolescence in the most lucrative markets from rival LAVs and alternative vaccine approaches, which have the potential to provide superior protection against serotype 2 infections and/or shorter dosing schedules.

Key Topics Covered:

Product Profiles

Dengvaxia: Dengue vaccines

List of Figures

Figure 1: Dengvaxia vaccine design

Figure 2: Dengvaxia for dengue fever - SWOT analysis

List of Tables

Table 1: Dengvaxia drug profile

Table 2: Dengvaxia pivotal trial data in dengue fever

Table 3: Dengvaxia ongoing late-phase trials in dengue fever

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/ff59bz/2018_dengvaxia?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180221006146/en/

Business Wire
www.businesswire.com

Last updated on: 21/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.